FDA Grants RMAT Designation to Tenaya Therapeutics' TN-401 Therapy

The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to TN-401, an investigational gene therapy from Tenaya Therapeutics intended to treat PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).

This regulatory milestone follows interim results from the company's RIDGE-1 Phase 1b/2 clinical trial, which indicated reductions in arrhythmia markers among study participants. The RMAT designation provides Tenaya with increased access to FDA guidance and potential pathways for accelerated approval, which is a step for a therapy targeting a severe genetic heart condition.

"RMAT designation underscores the recognition by regulators of the seriousness of PKP2-associated ARVC and the potential of TN-401 gene therapy to address its underlying cause," said Faraz Ali, Chief Executive Officer of Tenaya Therapeutics, in a statement. "This designation is supported by the interim data generated to date from our RIDGE-1 trial, which demonstrated reductions in daily rates of PVCs and NSVTs, as well as a favorable tolerability profile."

Understanding RMAT and Clinical Impact

The RMAT designation is a program created under the 21st Century Cures Act to expedite the development and review of regenerative medicine therapies. To qualify, a candidate must demonstrate preliminary clinical evidence that it has the potential to address an unmet medical need for a serious condition. By receiving this status, Tenaya gains frequent, intensive interactions with the FDA, which can help streamline the design of pivotal trials.

TN-401 is an AAV9-based gene therapy designed to restore the expression of the protein necessary for proper desmosomal complex function. The therapy targets mutations in the PKP2 gene, which are the most frequent genetic cause of ARVC. This condition affects approximately 40% of the total ARVC population, with an estimated prevalence of more than 70,000 individuals in the United States.

Strategic Regulatory Pathway

Tenaya’s regulatory strategy for TN-401 includes a combination of RMAT, Fast Track, and Orphan Drug designations. These statuses provide avenues for engagement with federal regulators as the company prepares to transition from early-stage testing to a pivotal trial.

"Together with Fast Track and Orphan Drug designations, RMAT enhances our ability to engage with the FDA as we strive to advance TN-401 toward a pivotal trial to bring this treatment to patients as quickly as possible," Ali said. "We look forward to sharing additional data from RIDGE-1 in the fourth quarter and providing an update on our ongoing discussions with regulators regarding pivotal trial plans for TN-401."

The company is focused on finalizing the design of its next-stage clinical studies, with updates expected by the end of the year.